Wire · opportunities
Head-To-Head Trial Reveals Better Immune-Dampening Drug For Psoriatic Arthritis
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 12 November 2026 · Fusion42 review
A clinical trial shows that bimekizumab, a newer interleukin inhibitor drug, is more effective at reducing symptoms of psoriatic arthritis than risankizumab, an older drug targeting the same condition. Bimekizumab led to higher rates of significant improvement and complete skin clearance, with a similar safety profile.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
Your drug development in autoimmune conditions must now compete with dual-targeting approaches like bimekizumab that show faster, more comprehensive results in clinical trials. Look to accelerate or rethink advancement paths or face losing ground to more effective therapies.
◆ Coverage
1 source · 12 Nov 2026
◆ Related on Wire
◆ Topics